Supplements and Featured Publications
2025 ESMO Congress: Focus on Breast Cancer
Summarizing Clinical Advances in the Management of MET Exon 14 Skipping Mutated–NSCLC
Summarizing Clinical Advances in the Management of MET Exon 14 Skipping Mutated–NSCLC
Moving the Needle With MEK Inhibition in Pancreatic Cancer
Prostate Cancer Awareness Month: The Evolving Role of Radioligand Therapy
Experts discuss the evolving role of radioligand therapy during Prostate Cancer Awareness Month.
Navigating TKI Selection in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia
Experts discuss TKI selection in chronic myeloid leukemia and acute lymphoblastic leukemia.
Navigating Second-Line Treatment Decisions in CLL
Raising Awareness About the Expanding Use of Immunotherapy in Recurrent Endometrial Cancer
Raising Awareness About the Expanding Use of Immunotherapy in Recurrent Endometrial Cancer
2025 Society of Hematologic Oncology Annual Meeting: Focus on GVHD
Navigating Frontline Treatment Decisions in Metastatic Pancreatic Cancer
Factors informing frontline treatment decisions in metastatic pancreatic cancer.
Outlining the Evolving Efficacy and QOL Outcomes Associated With ADT in Prostate Cancer
Outlining the Evolving Efficacy and QOL Outcomes Associated With ADT in Prostate Cancer
Optimizing and Individualizing Third-Line and Later Therapies for Metastatic CRC
Addressing Advances in Malignant PEComa Management
Exploring Further Avenues for Menin Inhibition in Acute Myeloid Leukemia
Navigating Pediatric-Inspired Regimens in Acute Lymphoblastic Leukemia
Gaining Insight Into Treatment Personalization in GIST
Reviewing Recent Developments in ROS1-Positive NSCLC
Data Informing Treatment Decisions and Strategies in HER2+ Breast Cancer
Supported in part by Daiichi Sankyo. Content produced and independently developed by OncLive.
Solidifying the Synergistic Activity of Toripalimab Plus Chemotherapy in Nasopharyngeal Carcinoma
Unpacking Pivotal Data Updates in Metastatic Breast Cancer Management
Sponsored in part by AstraZeneca and Daiichi Sankyo. Content produced and independently developed by OncLive.
Navigating Novel Endocrine Therapies in ER+ Breast Cancer
Going Beyond Immunotherapy in HPV-Negative Head and Neck Squamous Cell Carcinoma
Addressing Treatment Adherence With Liquid Drug Formulations in CML and ALL
Dissecting Emerging Data in Metastatic Breast Cancer
The Evolving Role of ESR1 Mutations in Metastatic Breast Cancer
This supplement is funded by AstraZeneca. The publisher is solely responsible for this content. AstraZeneca does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this supplement is not medical advice and does not replace independent medical judgment.
Targeting c-MET in Advanced Non–Small Cell Lung Cancer
Diving Into Therapeutic Decision-Making in Later-Line CLL
Molecular Testing and Evolving Treatment Strategies in HR+/HER2– Advanced Breast Cancer
The Evolution of Molecular Testing and Targeted Therapy in HR+/HER2– Breast Cancer
Treatment Considerations and Evolving Data in Advanced Melanoma After Checkpoint Inhibition
A dive into treatment considerations and ongoing research for advanced melanoma after PD-1 inhibition.
